5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 5.57▲ | 5.57▲ | 5.57▲ | 5.63▲ | 5.83▲ |
MA10 | 5.69▲ | 5.75▲ | 5.79▼ | 5.66▲ | 6.29▼ |
MA20 | 5.85▼ | 5.93▼ | 6.06▼ | 5.68▲ | 7.48▼ |
MA50 | 6.56▼ | 6.57▼ | 6.53▼ | 6.24▼ | 6.65▼ |
MA100 | 6.70▼ | 6.97▼ | 7.56▼ | 7.43▼ | 14.44▼ |
MA200 | 8.46▼ | 7.96▼ | 8.05▼ | 6.75▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.006▲ | -0.013▼ | -0.023▼ | 0.062▲ | -0.241▼ |
RSI | 43.310▼ | 42.937▼ | 42.159▼ | 49.238▼ | 44.353▼ |
STOCH | 29.853 | 27.469 | 24.077 | 40.304 | 17.144▼ |
WILL %R | -57.831 | -57.831 | -57.831 | -33.613 | -91.515▼ |
CCI | -13.740 | -18.391 | -20.952 | 110.783▲ | -68.471 |
MA | $MEDS Price Crossed Above MA(26) | Set Alert |
Friday, December 01, 2023 10:18 AM
Dozens of generic pharma companies are accused in the wide-ranging litigation of conspiring to fix price on hundreds of drugs. The companies in their filing opposed a request by Connecticut and other ...
|
Friday, December 01, 2023 08:55 AM
The analyst says the runway for obesity will remain attractive for years to come, and Novo Nordisk will be an outsized beneficiary of this trend, given its leadership in the space where it competes ...
|
Friday, December 01, 2023 07:06 AM
Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/11/23 | 5.62 | 6.173 | 5.614 | 5.85 | 13,200 |
29/11/23 | 5.60 | 5.65 | 5.40 | 5.65 | 2,300 |
28/11/23 | 5.65 | 5.65 | 5.40 | 5.42 | 2,900 |
27/11/23 | 5.74 | 5.95 | 5.65 | 5.65 | 5,500 |
24/11/23 | 5.80 | 5.80 | 5.439 | 5.60 | 900 |
22/11/23 | 5.41 | 5.81 | 5.41 | 5.53 | 2,600 |
21/11/23 | 5.377 | 5.95 | 5.30 | 5.61 | 6,400 |
20/11/23 | 6.25 | 6.25 | 5.66 | 5.66 | 6,100 |
17/11/23 | 5.75 | 6.00 | 5.75 | 6.00 | 5,200 |
16/11/23 | 5.80 | 5.81 | 5.52 | 5.60 | 2,900 |
|
|
||||
|
|
||||
|
|